Global Assisted Reproductive Technology Market is segmented By Technology, By Procedure, By Treatment, By Age-group, By Service Providers, By End-User, and By Region

Introduction:

Global Assisted Reproductive Technology (ART) Market is experiencing significant growth, driven by increasing infertility rates, advancements in medical technology, and growing awareness surrounding fertility treatments. The Global ART Market was estimated at 27.9 billion in 2024, and is expected to grow at a CAGR of 7.01% during the forecast period. With rising healthcare access, improved success rates, and expanding fertility tourism, ART services are becoming more widely available globally. In addition, advances in technology, such as AI-assisted embryo selection, improved culture media, and genetic screening tools, are revolutionizing the ART industry by increasing success rates and reducing costs.

Market analysis:

The global assisted reproductive technology (ART) market is experiencing robust growth, propelled by factors such as technological advancements in IVF and egg freezing, rising adoption of fertility preservation methods, and increasing support from healthcare organizations and governments. The growing number of individuals seeking ART services due to lifestyle factors, delayed pregnancies, and medical conditions is significantly boosting market demand. Technologies such as in vitro fertilization (IVF), intra-cytoplasmic sperm injection (ICSI), egg/sperm freezing, and genetic testing are at the forefront of ART developments. Additionally, advancements in embryology, cryopreservation techniques, and genetic screening are improving treatment success rates, making ART services more effective and accessible.

However, the market faces challenges that may hinder the accessibility to the market. One of the primary challenges is the high cost of ART treatments, which makes it unaffordable for a large segment of the population, particularly in low- and middle-income regions. Additionally, the lack of adequate insurance coverage for ART procedures exacerbates this issue. Regulatory complexities and ethical concerns surrounding ART practices, such as embryo freezing, surrogacy, and genetic screening, create barriers in some countries where stringent laws or lack of standardization exist.

Despite these challenges, the ART market presents substantial growth opportunities, particularly through expanding access to treatments, rising fertility tourism, and the continued development of cutting-edge technologies. The increasing collaboration between fertility clinics, biotech firms, and research institutions is expected to drive innovation and foster long-term growth.

Key trends in the global assisted reproductive technology (ART) market include the growing shift toward personalized treatments, driven by advances in genetic testing and diagnostics, enabling more tailored fertility solutions. The integration of artificial intelligence (AI) and machine learning in ART procedures is enhancing the accuracy of embryo selection, improving success rates, and reducing the time and cost of treatments. Additionally, the increasing use of cryopreservation and egg freezing is gaining popularity, allowing women to preserve their fertility for future use.

Segmental Analysis:

The Global Assisted Reproductive Technology Market analysis includes a comprehensive evaluation of key industry segments.

Based on technology, the global assisted reproductive technology market is segmented into In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Sperm Injection (ICSI) and Genetic Testing (PGT). The IVF segment accounted for the maximum share of 93.20% of the global revenue in 2024. Intrauterine Insemination (IUI) is growing segment as a less invasive, cost-effective option for mild infertility cases. Intracytoplasmic Sperm Injection (ICSI) is gaining popularity for male infertility treatment, particularly in cases of sperm motility or quantity issues.

Based on procedure, the global assisted reproductive technology is segmented into Fresh Embryo Transfer (ET), Frozen Embryo Transfer (FET) and Donor Egg/Donor Sperm ART. Fresh Embryo Transfer (ET) remains the preferred option for many patients as it typically results in higher pregnancy success rates, with embryos being transferred immediately after fertilization. However, Frozen Embryo Transfer (FET) is witnessing significant growth as it offers greater flexibility, allowing the use of previously frozen embryos, often leading to better outcomes for patients who have completed the IVF cycle. Donor Egg/Donor Sperm ART is increasingly used by couples experiencing infertility due to issues with egg or sperm quality, creating a growing niche in the market.

Based on treatment, the global assisted reproductive technology market is segmented into Male Infertility Treatment and Female Infertility Treatment. The Male Infertility Treatment segment is growing due to the rise in male infertility, especially relating to sperm motility, morphology, and count. However, Female Infertility Treatment continues to dominate with more than 40% of the Market, driven by increase in conditions such as ovulation disorders, polycystic ovary syndrome (PCOS), and endometriosis, which are prevalent causes of infertility in women.

Based on age group, the global assisted reproductive technology market is segmented into below 35 years, 35-40 years, and above 40 years. The 35-40 years segment is growing rapidly, with a market share of 35% and a CAGR of 12.2%. Above 40 years represents 20% of the market but is growing at the highest rate, with a CAGR of 13.2%, as delayed pregnancies become more common.

Based on service providers, the global art market is segmented into fertility clinics, hospitals, cryobanks and others. Fertility clinics segment dominates the market with a market share of 56%, due to specialization in ART treatments. Hospitals segment is growing at a smaller pace compared to fertility clinics, with a CAGR of 8.3%. Cryobanks play a significant role in preserving and providing donor eggs and sperm, contributing to the growing demand for ART. Other providers include genetic counselling services and specialized medical practitioners offering ART solutions.

Based on end-user, the global ART market is segmented into Couples with Fertility Issues, Single Parents, LGBTQ+ Community, Surrogacy Seekers, and Others. Couples with fertility issues segments continues to make up the majority of ART services at 67%, growing at a CAGR of 9.6%. Single parents and the LGBTQ+ community each represent around 10-15% of the market, growing at a CAGR of 12.0% due to increasing acceptance and demand for ART among these groups. Surrogacy seekers account for about 5% of the market.

Based on Region, The Global Assisted Reproductive Technology Market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. Europe dominated the industry in 2024 and accounted for the largest revenue share of more than 41.18%. The substantial market share can be attributed to factors such as rising infertility rates, growing awareness about fertility treatments, technological innovations, and government support. For example, the European Society of Human Reproduction and Embryology reports that around 24 million people in the European Union are affected by infertility, the highest rate globally. North America is anticipated to experience notable growth throughout the forecast period, driven by the positive results observed in patients undergoing fertility treatments. Asia Pacific is the fastest-growing region, with a CAGR of 13.5% as increasing awareness and accessibility to ART services in countries like China, India, and Japan are driving market growth.

Company analysis:

Several key companies dominate the ART market, offering a range of fertility treatments and services. These companies leverage advancements in technology and increasing demand for ART procedures, driven by rising infertility rates. Key players include: CooperSurgical, Inc., Merck KGaA, Vitrolife AB, Ferring Pharmaceuticals, Genea Biomedx, Igenomix, Embryolab, HRC Fertility, The Fertility Clinic (TCF), CryoLife, Inc., Klinikum St. Georg, Medicover Fertility, Hamilton Thorne, Cozart Technologies, Irvine Scientific

Some key developments in these companies include:

• In February 2024, Merck Group announced the launch of an advanced fertility drug designed to improve the chances of successful IVF treatments by reducing the risk of ovarian hyperstimulation syndrome (OHSS). This launch highlights the companys commitment to enhancing ART treatment outcomes.
• In May 2024, Ferring Pharmaceuticals entered into a partnership with a biotechnology firm to develop a new gene-editing technology aimed at improving embryo selection during IVF treatments. This collaboration is expected to significantly reduce the number of failed IVF cycles and increase the success rate of fertility treatments.
• In June 2024, CooperSurgical launched a new AI-powered platform called PGTai platform to enhance embryo quality assessment during IVF procedures. This platform uses machine learning algorithms to analyze embryo growth and development, improving the chances of successful pregnancy.
• In September 2024, HRC Fertility unveiled the Dream Time package. This package integrates the Geri time-lapse incubation system with comprehensive IVF services, providing patients with advanced technology to improve embryo development processes.

The global assisted reproductive technology (ART) market is experiencing rapid growth, driven by increasing infertility rates, advancements in fertility treatments, and heightened awareness about reproductive health. Technological innovations such as in vitro fertilization (IVF), intrauterine insemination (IUI), and genetic testing are revolutionizing the ART landscape, offering enhanced success rates and better outcomes. The growing acceptance of ART across diverse demographics, including single parents and the LGBTQ+ community, is further fueling market expansion. With rising demand for more personalized fertility treatments, advancements in cryopreservation and embryo transfer techniques are also gaining traction. In addition, the increasing availability of fertility clinics and healthcare infrastructure, combined with supportive government initiatives, is accelerating access to ART services. Despite challenges like high treatment costs and regulatory complexities, the ART market presents significant opportunities for growth and innovation in the coming years.

Segmentation:

By Technology

• In Vitro Fertilization (IVF)
• Intrauterine Insemination (IUI)
• Intracytoplasmic Sperm Injection (ICSI)
• Genetic Testing (PGT)

By Procedure

• Fresh Embryo Transfer (ET)
• Frozen Embryo Transfer (FET)
• Donor Egg/Donor Sperm ART

By Treatment

• Male Infertility Treatment
• Female Infertility Treatment

By Age Group

• Below 35 Years
• 35-40 Years
• Above 40 years

By Service Providers

• Fertility Clinics
• Hospitals
• Cryobanks
• Others

By End-users

• Couples with Fertility Issues
• Single Parents
• LGBTQ+ Community
• Surrogacy Seekers
• Others

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Research Methodology

At Stats and Research, we adopt a rigorous, data-driven methodology to ensure our market research reports provide accurate, reliable, and actionable insights. Our structured approach combines both qualitative and quantitative research techniques, utilizing advanced data analytics, statistical modelling, and market intelligence tools to offer well-rounded perspectives on the market.

Our research process follows four key stages:

1. Research and Data Collection

Our data collection is based on a comprehensive, three-pillar approach:

Primary Research: We directly engage with industry leaders, executives, product managers, investors, distributors, regulatory bodies, and end-users. This is done through structured interviews, surveys, and consultations to gather real-time insights.

Secondary Research: We examine secondary data sources like company financials, government reports, regulatory filings, investor presentations, whitepapers, trade association reports, and industry publications to build a foundational understanding of the market.

Product or Services Mapping: We analyze product portfolios, service offerings, and revenue breakdowns across global, regional, and local levels. This helps us assess market share, product penetration, and competitive positioning, identifying industry trends and growth opportunities.

Key Data Sources:

Government and International Databases: OECD, FAO, IMF, World Bank, WTO, National Statistics Bureaus, etc.

Industry Journals & Publications: Technium, Science, MDPI, MarketLine, ResearchGate, etc.

Company Reports: Annual reports, press releases, investor briefings, regulatory disclosures, etc.

Trade Associations & Market Intelligence Databases: Insights from financial institutions, manufacturing groups, and professional bodies.

This comprehensive approach ensures that our findings are grounded in credible and verified data sources.

2. Data Pre-Processing and Standardization

In this stage, we focus on ensuring data accuracy and consistency through:

Data Refinement: We identify and resolve gaps, inconsistencies, and anomalies in the collected data to ensure its completeness and reliability.

Standardization: Data is converted into uniform formats and measurement units, enabling seamless comparison across regions, products, and segments.

This meticulous preparation ensures that the data used in our analysis is clean, validated, and optimized for precise market analysis.

3. Market Estimation and Forecasting

Our market estimation model combines both Top-Down and Bottom-Up approaches to ensure a well-rounded and validated market assessment:

Top-Down Approach: We begin with macro-level estimations of market size, breaking it down by region, industry segment, and product category, using key economic indicators and market dynamics.

Bottom-Up Approach: We aggregate data from individual companies, product categories, and regional markets to ensure micro-level accuracy in our estimates.

Each forecast model is customized to the specific characteristics of the market, guaranteeing precision in future projections.

4. Quality Assurance and Validation

To ensure the highest level of data accuracy and reliability, our research undergoes multiple layers of validation:

Data Triangulation: We cross-verify insights from both primary and secondary sources to ensure consistency and reliability.

Expert Review Panels: We collaborate with industry professionals and market analysts to validate our findings and methodologies.

Client & Stakeholder Feedback: We ensure that the research findings align with the needs and expectations of our clients and stakeholders.

Plausibility & Consistency Checks: We perform historical data validation and time-series tests to ensure the logical consistency of our market estimates.

This rigorous validation process guarantees that our insights are credible, precise, and actionable.

Conclusion

By combining structured data collection, robust estimation methods, and comprehensive validation, our methodology ensures that we deliver high-quality, accurate market insights tailored to meet the specific needs of our clients.